GlaxoSmithKline Egypt S.A.E. specializes in the development, manufacture and marketing of medicines. Their products are for the treatment of diabetes, asthma, cancer, hepatic viruses, infections, allergies and gastro-intestinal and cardiovascular diseases.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-08-09	EGP 477.26	+20.00%	1,125,927
26-08-06	EGP 397.72	+20.00%	2,414,902
26-08-05	EGP 331.44	-20.00%	346,697
26-08-04	EGP 414.30	+20.00%	449,150
26-08-03	EGP 345.25	+20.00%	559,339

End-of-day quote Egyptian Exchange

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Egyptian Exchange Other stock markets 2026-08-09			5-day change	1st Jan Change
477.26 ^EGP	+20.00%		+99.06%	+649.82%

05-17	GlaxoSmithKline Q1 consol net profit EGP 4.7 million	RE
03-12	GlaxoSmithKline S.A.E Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	39.86B 801M 692M 647M 593M 1.12B 76.27B 1.13B 7.58B 2.97B 38.19B 3.01B 2.94B 126B	P/E 2024	17.3x	P/E 2025	24.9x
Enterprise Value	39.46B 793M 685M 640M 587M 1.11B 75.51B 1.12B 7.5B 2.94B 37.81B 2.98B 2.91B 125B	EV / Sales 2024	1.02x	EV / Sales 2025	1.32x
Free-Float	2.91%	Yield 2024 *	-	Yield 2025	1.57%

05-17	GlaxoSmithKline Q1 consol net profit EGP 4.7 million	RE
03-12	GlaxoSmithKline S.A.E Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-12	GlaxoSmithKline FY dividend EGP 0.75 per share	RE
03-12	GlaxoSmithKline FY consol profit EGP 213.2 million	RE
12-29	GlaxoSmithKline S.A.E announces Annual dividend, payable on January 14, 2026	CI
11-18	GlaxoSmithKline S.A.E Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-13	GlaxoSmithKline Q3 consol loss EGP 34.8 million	RE
25-08-12	GlaxoSmithKline S.A.E Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-08-12	GlaxoSmithKline posts Q2 consol profit EGP 5.9 mln	RE
25-05-14	GlaxoSmithKline S.A.E Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-05-14	Glaxosmithkline Reports Q1 Net Profit EGP 43.5 Million	RE
25-03-09	GlaxoSmithKline S.A.E Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-03-09	Glaxosmithkline FY Dividend EGP 1 Per Share	RE

22-03-10	GlaxoSmithKline E : Glaxo Smith Kline (BIOC.CA) - Listing Committee Decision	PU
21-12-20	GSK hires former Tesco boss Sir Dave Lewis to head up £40bn spin-off	AQ

GlaxoSmithKline S.A.E Stock

Stocks

BIOC

EGS38171C012

Pharmaceuticals

Valuation: GlaxoSmithKline S.A.E

Chart: GlaxoSmithKline S.A.E

Latest news : GlaxoSmithKline S.A.E

Press Releases: GlaxoSmithKline S.A.E

Quotes and Performance

Course Extremes

Managers and Directors: GlaxoSmithKline S.A.E

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+20.00%
1 week	+99.06%
Current month	+99.06%
1 month	+551.64%
3 months	+563.05%
6 months	+597.44%
Current year	+649.82%

1 week	265.2	497.16
1 month	73	497.16
Current year	55.1	497.16
1 year	46.08	497.16
3 years	24.7	497.16
5 years	16.66	497.16
10 years	0	497.16

Director	Title	Age	Since
Sherine El-Ansari BRD	Director/Board Member	-	-
Ashraf Mohammed Ibrahim Mansour CHM	Chairman	-	-
Munir Ghabour Hanna BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GLAXOSMITHKLINE S.A.E	+20.00%	+99.06%	+887.09%	+1,418.97%	667M
ELI LILLY AND COMPANY	-0.52%	+3.21%	+89.52%	+127.32%	1,057B
JOHNSON & JOHNSON	+0.88%	+1.13%	+49.56%	+49.69%	625B
ABBVIE INC.	+0.89%	-1.95%	+24.23%	+64.44%	435B
ROCHE HOLDING AG	+0.71%	+3.87%	+49.07%	+37.85%	363B
NOVARTIS AG	+0.64%	-0.49%	+33.94%	+40.01%	296B
ASTRAZENECA PLC	+0.39%	-5.83%	+8.92%	+7.85%	249B
AMGEN INC.	+1.51%	+6.69%	+42.58%	+57.57%	222B
NOVO NORDISK A/S	+3.92%	-0.46%	-5.56%	-52.32%	209B
GILEAD SCIENCES, INC.	+1.80%	+2.30%	+11.56%	+66.35%	165B
Average	+3.02%	+4.60%	+119.09%	+181.77%	362.15B
Weighted average by Cap.	+0.66%	+1.22%	+48.88%	+64.88%

	2024	2025
Net sales	2.99B 60.12M 51.94M 48.54M 44.51M 83.83M 5.72B 85.1M 568M 223M 2.87B 226M 221M 9.48B	3.73B 74.99M 64.78M 60.55M 55.52M 105M 7.14B 106M 709M 278M 3.57B 282M 275M 11.82B
Net income	174M 3.5M 3.02M 2.82M 2.59M 4.88M 333M 4.95M 33.07M 12.98M 167M 13.13M 12.84M 551M	213M 4.29M 3.7M 3.46M 3.17M 5.98M 408M 6.07M 40.53M 15.91M 204M 16.09M 15.74M 676M
Net Debt	44.01M 885K 764K 714K 655K 1.23M 84.21M 1.25M 8.36M 3.28M 42.17M 3.32M 3.25M 139M	-398M -8M -6.91M -6.46M -5.92M -11.15M -761M -11.32M -75.63M -29.68M -381M -30.03M -29.38M -1.26B